Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE) research hub

A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy

This study is looking at a new medicine called Elsunersen for children with a specific type of epilepsy caused by changes in the SCN2A gene. It wants to see how well the medicine reduces seizures and if it's safe to use. It's a key stage in testing this potential new treatment.